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Supplementary Table 1. Frequency of relapse MRI findings over the total of relapses 
  NMOSD (+) NMOSD (-) MOG-AD 
STM 16 (12.5) 5 (5.1) 3 (11.1) 
LETM 54 (42.9) 65 (58.9) 12 (46) 
Optic nerve lesions 38 (30.4) 31 (28.2) 14 (55.6) 
Area postrema lesions 2 (1.8) 3 (2.6) - 
Diencephalic lesions 2 (1.8) 3 (2.6) - 
Hemispheric white matter lesions 2 (1.8) 3 (2.6) - 
Other 2 (1.8) - - 
Unknown 2 (1.8) 3 (2.6) 6 (22.2) 
STM: short-segment transverse myelitis, LETM: longitudinally extensive transverse 
myelitis, NMOSD (+): AQP4-ab-positive NMOSD, NMOSD (-): AQP4-ab-negative NMOSD, 
MOG-AD: MOG-associated diseases. 
Supplementary Table 2. Long-term treatment of the studied cohort.  







  N, (%) N, (%) N, (%) 




















Switched first treatment 
 
17 (44.7) 28 (40.6) - 
































Switched second treatment 
 
1 (11.1) 8 (30.7) - 




























Supplementary table 3. Predictors of complete remission in NMOSD (positive and 
negative) patients from relapses 
  OR 95%CI P  
Age at disease onset 2.27 2.11-4.12 0.002  
Female 0.57 0.12-2.52 0.461  
Symptom at onset 0.77 0.43-1.23 0.862  
Time from onset of relapse to start of treatment 0.95 0.82-1.56 0.885  
Duration of long-term immunosuppressive 
treatment 
0.88 0.65-1.65 0.421  
First line treatment for relapse 1.03 0.67-1.78 0.223  
  
Supplementary table 4. Predictors of complete remission in MOG-AD patients from 
relapses 
  OR 95%CI P  
Age at disease onset 1.56 1.22-2.01 0.03  
Female 0.54 0.34-2.13 0.237 
Symptom at onset 1.12 0.34-3.12 0.652 
Time from onset of relapse to start of 
treatment 
1.29 0.65-2.65 0.126 
Duration of long-term 
immunosuppressive treatment 
0.96 0.23-3.14 0.17  
First line treatment for relapse - - -  
  
 
 
